<DOC>
	<DOCNO>NCT00842465</DOCNO>
	<brief_summary>Prolactin know play important role breast development differentiation . Thus proliferative breast disease good model unravel PRl / PRLR function proliferative process . The aim project identify characterize new mutant prolactin receptor gene within cohort benign malign breast disease low high occurrence frequency human population</brief_summary>
	<brief_title>Prolactin Receptor Breast Diseases</brief_title>
	<detailed_description>There currently know genetic disease link prolactin ( prl ) receptor ( prlR ) human . In previous work , identify new mutation prolactin receptor lead 's constitutive activation cell proliferation signal cascade ( i.e . MAP kinases ) . This result suggest PRLR mutant may strong physiopathological impact breast diseases etiology and/or development and/or evolution . Based , pursue identification new PRLR mutant various breast disease continue vitro functional characterization analyse vivo consequence breast tissue sample collect within woman . 1 . In first time wish confirm previous result multiple fibroadenoma ( MFA ) . The current cohort augment 30 35 new patient year . We confirm vitro result vivo tumoral peri-tumoral tissue sample . 2 . We wish extend study rare breast pathology ( i.e . gigantomastia , phyllodies tumor , giant fibroadenoma ) common one ( simple fibroadenoma ) demonstrate link simple FA MFA . 3. third time try determinate whether constitutive activation PRLR lead enhance occurrence benign / malign transition .</detailed_description>
	<mesh_term>Breast Diseases</mesh_term>
	<mesh_term>Fibrocystic Breast Disease</mesh_term>
	<criteria>Inclusion criterion : benign breast diseases 10 &lt; age &lt; 25 simple FA 10 &lt; age &lt; 50 disease .no hormonal treatment least 3 month patient take cyproterone acetate ; 1 month ovariesinterfering hormonal treatment , 1 week ovariesnoninterfering hormonal treatment . Signature informed consent form ( icf ) patient legal representative ( patient age 18 . ) breast cancer : breast cancer plan surgery age &gt; 55 year post menopausal menopause substitution treatment signature icf control group : 18 &lt; age &lt; 60 signature icf Exclusion criterion : signature conformity icf social security</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Breast disease ,</keyword>
	<keyword>human mutation ,</keyword>
	<keyword>prolactin receptor ;</keyword>
	<keyword>breast cancer</keyword>
</DOC>